IL-23p19 Antagonists vs. Ustekinumab for Treatment of Crohn’s Disease: A Meta-analysis of Randomized Controlled Trials

By sjmartinez • March 13, 2025

Dziegielewski C, Yuan Y, Ma C, Boland BS, Chang JT, Syal G, Vuyyuru SK, Peyrin-Biroulet L, Jairath V, Singh S. IL-23p19 Antagonists vs. Ustekinumab for Treatment of Crohn's Disease: A Meta-analysis of Randomized Controlled Trials. Am J Gastroenterol. 2025 Mar 12. doi: 10.14309/ajg.0000000000003406. Epub ahead of print. PMID: 40071763.

Tags: Digestive Diseases, Publications

Permeability of the intestinal epithelial and blood-brain barriers as therapeutic targets in inflammatory depression

Ho TC, Vignolle GA, Wang DJJ, Church A. Permeability of the intestinal epithelial and blood-brain barriers as therapeutic targets in inflammatory depression. Brain Behav Immun.[...]

Targeting lipidated amino acid deficiency mitigates fibrosis via a PPARα/CCL2 axis in metabolic dysfunction-associated steatohepatitis models

Anand SK, Das S, Arias F, Richard KS, Rohilla S, Ghrayeb A, McKinney MP, Wang L, Tan L, Ding J, Kumar D, Pandey N, Lee[...]

Fibroblasts restrain gut inflammation by IGF1-dependent regulation of innate lymphocytes

Lin Q, Liu RE, Wang Q, Kang L, Chen B, Lu Y, Zhang Y, Gu Z, Zhou Y, Liu H, Xu X, Cao Z, Tang[...]